MasterControl, a leading provider of quality management and manufacturing software solutions, today announced the appointment of Kelly Starman as Chief M...
Financial results of Q2 2024 Group net sales up organically by 1.7% to € 5.4 billion EBITDA pre down 0.8% organically to € 1...
– Record revenue of $81.5M in 3QFY24, an increase of 28% over $63.7M in 3QFY23 – – Gross margin improved to 43.3% in 3QFY24, incre...
In a recent Q&A session with BioPharma BoardRoom, Gavin Kurgan, Bioinformatics Applications Development Manager at Integrated DNA Technologies ...
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended June 29...
Revenue of $3,814 million GAAP Net Income of $363 million, Adjusted EBITDA of $887 million GAAP Diluted Earnings per Share of $1.97, Adjusted D...
Shanghai Junshi Biosciences Co., a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercializati...
Milestones reached in cardiovascular, renal, metabolic health (CRM), and oncology Further data read-outs expected in 2024 in oncology, mental health, ...
Exact Sciences, a leading provider of cancer screening and diagnostic tests, announced that it awarded a total of $1.5 million to 28 organiza...
net sales grew +11% (cc1, +9% USD) with core operating income up +19% (cc, +17% USD) Sales growth driven by continued strong performance from Entr...
In this insightful interview with Martin Westberg, Vice President and General Manager of Cell Therapy at Cytiva, BioPharma BoardRoom delve into the tr...
Financial results of Q1 2024 Healthcare with strong performance Electronics increases sales and earnings organically, driven by higher demand for semic...
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2024. For the quarter, revenue was $1.01 bil...
First-quarter 2024 total net sales were $610.8 million, a decrease of 9.8 percent compared to $676.8 million reported for the first quarter of 2023...
© 2024 Biopharma Boardroom. All Rights Reserved.
